Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children | Zendy

Wael ElMatary | Zendy; Thomas D. Walters | Zendy; Hien Q. Huynh | Zendy; Jennifer deBruyn | Zendy; David Mack | Zendy; Kevan Jacobson | Zendy; Mary Sherlock | Zendy; Peter Church | Zendy; Eytan Wine | Zendy; Matthew Carroll | Zendy; Eric I. Benchimol | Zendy; Sally Lawrence | Zendy; Anne M. Griffiths | Zendy

Open Access

Higher Postinduction Infliximab Serum Trough Levels Are Associated With Healing of Fistulizing Perianal Crohn’s Disease in Children

Author(s) -

Wael ElMatary,

Thomas D. Walters,

Hien Q. Huynh,

Jennifer deBruyn,

David Mack,

Kevan Jacobson,

Mary Sherlock,

Peter Church,

Eytan Wine,

Matthew Carroll,

Eric I. Benchimol,

Sally Lawrence,

Anne M. Griffiths

Publication year - 2018

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izy217

Subject(s) - infliximab , medicine , crohn's disease , trough (economics) , trough level , inflammatory bowel disease , gastroenterology , disease , crohn disease , tacrolimus , transplantation , economics , macroeconomics

There is some evidence in adults that higher serum infliximab (IFX) levels are needed to adequately treat fistulizing perianal Crohn's disease (CD). However, data in children are lacking. We aimed to determine postinduction serum trough IFX levels that are associated with healing of fistulizing perianal CD (PCD) at week 24.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research